Entera Bio names Riccardo Camisasca as chief medical officer

Entera Bio Ltd. (NASDAQ: ENTX) announced on August 18, 2026 the appointment of Riccardo Paolo Camisasca, M.D. as Chief Medical Officer, effective immediately. The Company appointed Dr. Riccardo Paolo Camisasca as the Company's Chief Medical Officer, effective immediately.¹

Dr. Camisasca brings more than three decades in drug development. He is a physician with over 30 years of experience across clinical development, medical affairs, regulatory strategy and R&D leadership, and most recently served as Global Head of Research & Development at Sumitomo Pharma Switzerland, a role in which he oversaw the merging of R&D functions across Urovant, Enzyvant, Altavant and Myovant, handling clinical development, trial execution and alliance management across those four business units.¹ Earlier in his career, he led clinical development and medical affairs at Bial, and held progressively senior roles at Syneos Health, Takeda and Novartis.¹ Before that, he worked as a physician and researcher at San Raffaele Hospital in Milan for about ten years, focusing partly on endocrinology and metabolic disease, and holds a Medical Degree with honors and a specialization in Clinical Pharmacology from the University of Milan.¹

The hire is tied to Entera's plans to advance EB613, its lead oral peptide candidate. EB613, an oral formulation of PTH(1-34) teriparatide, is being developed as the first oral, once-daily anabolic tablet for osteoporosis.¹ In prior testing, a Phase 2 trial ran six months, enrolled 161 patients, was placebo-controlled, and achieved all biomarker and bone mineral density endpoints in women with postmenopausal osteoporosis or low BMD, without notable safety issues, showing dose-related gains in bone formation markers, declines in resorption markers, and BMD increases at the spine, hip and femoral neck.¹ The company said Camisasca's arrival strengthens its readiness for late-stage clinical execution as it moves toward Phase 3.